Post-Doctoral Researchers

The OxCD3 currently has 8 Post-Doctoral researchers based between the University of Oxford's Institute of Biomedical Engineering, the Department of Oncology and the MRC Weatherall Institute of Molecular Medicine.

Work Package 1 - Ultrasound & Solid Nanoparticles for Viral Delivery (WP1)

Dr Christophoros Mannaris

Ultrasound in drug delivery applications
Christophoros graduated from the University of California, San Diego in 2003 with a Bachelor of Science, Bioengineering ABET and then worked as a Research Assistant at the La Jolla Bioengineering Institute before embarking on a PhD at the University of Cyprus. His PhD focused on Ultrasound enhanced drug delivery and the use of ultrasound contrast agents for the detection and quantification of neovascularisation in atheromatic plaques in the carotid. Christophoros joins OxCD3 working with Professor Constantin Coussios on ultrasound in drug delivery applications.
Dr Brian Lyons

Cancer biology and virotherapy delivery
Brian joins the Oxford Centre for Drug Delivery Devices (OxCD3) as part of a collaboration with the Seymour group in Oncology and is working to enhance the delivery of oncolytic adenovirus through conjugation of sonosensitive nanoparticles which facilitate initiation of acoustic cavitation whilst simultaneously shielding the virus from the immune system. Brian completed his BSc in Chemistry (Hons) at the National University of Ireland Galway and then relocated to Australia where he spent two years working as a Synthetic Chemist for a Sydney-based R+D pharmaceutical company investigating novel oncology drugs. He obtained his PhD from the University of Sydney under the supervision of Professor Roger Truscott where his research focused on the age-related changes that occur in long-lived human proteins and their implications for healthy ageing. He continued his research at Sydney University as a postdoctoral researcher where he investigated the mechanisms of Alzheimer’s disease and cataract. As a postdoctoral scholar within the Davis group at Oxford, Brian worked a variety of projects all of which were based on chemically modifying proteins, peptides and sugars to understand, exploit and modify biomolecular function.
Work Package 2: US-triggered liposomes for the delivery of radiopharmaceuticals

Dr Joshua Owen

Nanoencapsulation and liposomal formulation for drug delivery applications
 Joshua graduated with an MSci in Chemistry from UCL before spending an exchange year at the California Institute of Technology where he joined the Stoltz group. On completion of a Master's project at the Royal Institution of Great Britain in 2011, he commenced a DPhil at the University of Oxford supervised by Professor Eleanor Stride. His DPhil research focused on the development of magnetic microbubbles as controllable drug delivery vehicles and ultrasound contrast agents as part of a collaborative project with the Royal Institution and the Royal Free Hospital. Having successfully gained his DPhil in 2014, Joshua joins OxCD3 working with Professor Robert Carlisle on nanoencapsulation and liposomal formulation for drug delivery applications.
Work Package 3: Shock wave delivery of antibody fragments

Dr Jing Zhang

Protein-protein interactions in cancer and methods for drug delivery
Jing graduated from Nanjin University of Technology, China in 2006 with BEng degree in Pharmaceutical Engineering before commencing a PhD at the University of Sheffield where his research focused on the mechanism of structural specific endo/exo-nuclease. On completion of his PhD, Jing joined Professor Terry Rabbitts research group in 2012 where he continues his research on protein-protein interactions in cancer and methods for drug delivery.
Dr Shamit Shrivastava

Shamit graduated from the Indian Institute of Technology, India with a B.Tech in Mechanical Engineering in 2008. He was also an undergraduate research fellow in Tissue Engineering with Professor Ali Khademhosseini at Harvard Medical School, Cambridge, USA before joining the group of Professor Matthias F. Schneider at Boston University in 2009 for his MS/PhD in Biomedical Engineering. The topic of his thesis was “Nonlinear solitary sound waves in lipid membranes and their possible role in biological signalling”. Shamit joined the OxCD3 team in June 2015 where he will be investigating the shock wave induced biophysical changes at cellular interfaces.  
Work Package 4: siRNA Delivery for Targeted Imaging and Therapy of Brain Metastases

Dr Luca Bau
Dr Luca Bau

Microbubble Mediated Drug Delivery combining Ultrasound and Magnetic Targeting
Luca received his PhD in Chemistry from the University of Padova (Italy) in 2010, then completed a post-doctoral fellowship at Arizona State University on the design and synthesis of metallopetides containing non-natural amino acids acting as enzyme micmics for DNA cleavage and water oxidation. Between 2010-2012, he worked as  a post-doctroral fellow at the Universiy of Padova, on the design of fluorescent probes for measuring chloride currents in neuronal cells. He joined the University of Oxford as a post-doctoral research assistant in 2012, working on developping quality control protocols for a commercial polysaccharide starting material.  He subsequently joined OxCD3 in 2016 to work on the synthesis of stimulus-responsive droplets for brain drug delivery applications. 
Dr Sarah Peeters
Dr Sarah Peeters

Targeted Drug Delivery to Brain Tumours
Sarah graduated from the University of Maastricht, The Netherlands, in 2010 with a Master of Science (MSc) in Molecular Life Sciences, Clinical Molecular Sciences. She commenced a PhD at the University of Maastricht at the department of Radiation Oncology under the supervision of Professor Philippe Lambin and Dr. Ludwig Dubois. Her research focussed on imaging and targeting of the hypoxic tumour microenvironment and she successfully gained her PhD title in 2015. Sarah joined the Department of Oncology in 2015, working with Professor Nicola Sibson. Her research project is part of the Oxford Centre of Drug Delivery Devices (OxCD3) and focusses on the detection and targeting of early stage brain metastasis.


© Copyright OXCD3 2016